VP-16-213 (etoposide): The mandrake root from Issyk-Kul
Authors:
- Nicholas J. VogelzangNVNicholas J. Vogelzang
- Derek RaghavanDRDerek Raghavan
- B.J. KennedyBKB.J. Kennedy
- 1 January 1982
- journal article
- clinical trial
- Published by Elsevier in The American Journal of Medicine
- Vol. 72 (1) , 136-144
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Etoposide (VP-16-213)Cancer Treatment Reviews, 1979
- Multicompartment Pharmacokinetic Model of 4′-Demethylepipodophyllotoxin 9-(4,6-O-Ethylidene- β-D-glucopyranoside) in HumansJournal of Pharmaceutical Sciences, 1978
- VM 26 and VP 16–213: A comparative analysisCancer, 1977
- Effect of VP-16-213 on the intracellular degradation of DNA in HeLa cellsBiochemistry, 1976
- Combination chemotherapy with 4′Demethylepipodophyllotoxin 9-(4,6-0-ethylidene-β-d-glucopyranoside), VP 16–213 (NSC 141540) in L1210 Leukemia1976
- Response of L1210 to combinations of cytosine arabinoside and VM-26 or VP16-213European Journal of Cancer (1965), 1975
- Cytofluorometric studies on the action of podophyllotoxin and epipodophyllotoxins (VM-26, VP-16-213) on the cell cycle traverse of human lymphoblasts.Journal of Cell Biology, 1975
- EPEG, a new antineoplastic epipodophyllotoxinClinical Pharmacology & Therapeutics, 1975
- Epipodophyllotoxin VP 16213 in Treatment of Acute Leukaemia—Haematosarcoma and Solid TumoursBMJ, 1973
- Mitosis-inhibiting natural products. 24. Synthesis and antimitotic activity of glycosidic lignan derivatives related to podophyllotoxinJournal of Medicinal Chemistry, 1971